Large gap with delayed quotes
|
Last quote
11/04/2025
-
02:00:00
|
Bid
11/04/2025 -
13:00:00
|
Bid Volume |
Ask
11/04/2025 -
13:00:00
|
Ask Volume |
|---|---|---|---|---|
|
197.85
+0.34
(
+0.17% )
|
160.96
|
100 |
219.27
|
100 |
Analysis date: 31.10.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 19.09.2025.
Interest
Strong
Strong
Three stars since 17.10.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 17.10.2025 at a price of 190.23.
Evaluation
Strongly undervalued
Strongly undervalued
Based on its growth potential and our own criteria, we believe the share price is currently undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 16.09.2025.
4wk Rel Perf
9.62%
9.62%
The four-week dividend-adjusted overperformance versus SP500 is 9.62%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 13.12.2024.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.90%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 5.14%.
Mkt Cap in $bn
5.72
5.72
With a market capitalization between $2 & $8bn, KRYSTAL BIOTECH is considered a mid-cap stock.
G/PE Ratio
1.51
1.51
A "Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings" ratio higher than 1.5 indicates that the stock's price presents a discount to growth >40% in this case.
LT P/E
21.38
21.38
The estimated PE is for the year 2027.
LT Growth
32.35%
32.35%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
11
11
Over the last seven weeks, an average of 11 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
45
45
For 1% of index variation, the stock varies on average by 0.45%.
Correlation
0.18
0.18
Stock movements are totally independent of index variations.
Value at Risk
63.46
63.46
The value at risk is estimated at USD 63.46. The risk is therefore 32.13%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
22.11.2024
22.11.2024